-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Cerevel Therapeutics Holdings, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from Q3 2021 to Q1 2024.
- Cerevel Therapeutics Holdings, Inc. Earnings Per Share, Diluted for the quarter ending March 31, 2024 was -0.73 USD/shares, a 8.96% decline year-over-year.
- Cerevel Therapeutics Holdings, Inc. Earnings Per Share, Diluted for the twelve months ending March 31, 2024 was -2.73 USD/shares, a 7.91% decline year-over-year.
- Cerevel Therapeutics Holdings, Inc. annual Earnings Per Share, Diluted for 2023 was -2.67 USD/shares, a 15.1% decline from 2022.
- Cerevel Therapeutics Holdings, Inc. annual Earnings Per Share, Diluted for 2022 was -2.32 USD/shares, a 40.6% decline from 2021.
- Cerevel Therapeutics Holdings, Inc. annual Earnings Per Share, Diluted for 2021 was -1.65 USD/shares, a 17.9% increase from 2020.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)